New course will help navigate emerging field of longevity – an industry that is going to change the world.
Investing in a new mega trend can be challenging; as well as entering a new market, there is a great deal to learn and understand – new terminology, new science, new risks and new opportunities.
Investing in Longevity 101 is a new online course designed to help investors, and all those interested in participating in this new economy, to navigate the sector – this includes entrepreneurs, executives, clinicians, policy makers, &c.
The course’s target audience, incudes, but is not limited to:
- Venture capitalists
- Fund managers
- Angel investors
- Pharma executives & biotechnology professionals
- Medical doctors pursuing continuing medical education
- Medical students
Longevity.Technology: Launching shortly, the course content for Investing in Longevity 101 addresses both longevity biotech and non-biotech, reflecting the current segmentation of the longevity market.
There are companies like supplement manufacturers, clinics and biomarker vendors that are raising capital and generating revenues today, and there are longevity biotechs that are progressing through clinical trial phases – a growing number of them ‘in human’. Plus, there are myriad companies not far behind, all looking for multiple millions in investment that can help them maintain their progress and accelerate to clinic or market.
Education is key, and really understanding the longevity space will help investors benefit from its incredible opportunities – and help longevity benefit from much-needed investment. We gathered the course founders – Evelyne Bischof, Phil Newman, Ricardo Gaminha Pacheco, Jiayi Song and Alex Zhavoronkov – round a virtual table to find out more.
Phil Newman, Longevity.Technology CEO and one of the course’s founders told us: “Whether your interest is ‘longevity now’ or ‘longevity next’ there is always going to be risk and reward for investors – this is why Investing in Longevity 101 is so necessary; the longevity economy is building traction, and we want to ensure that investors and those seeking investment have a good platform of knowledge from which to work.”
Insilico Medicine CEO Alex Zhavoronkov, PhD, who is also a course founder, said: “Investing is a risky business and the cost to put one drug on the market can hit $2 billion – the cost, time, and failure rate in longevity biotechnology is likely to be higher. So far, nothing in longevity biotechnology worked – there are no success stories. Hype cycles in longevity correlate with macro economic cycles, and investors need to understand where to deploy capital.”
The course creators are putting the finishing touches to the program, and it will be launching in the coming weeks; if you are interested in pre-registering so you don’t miss out you can do so using this form:
Alex Zhavoronkov on longevity impact
I think that this course is going to be extremely valuable for not only investment professionals, but also high school students, university students and lay people alike. It introduces the most exciting and the most impactful industry – and one that is going to change the way we think about life in general. I think it’s the most impactful industry on the planet.
Evelyne Bischof on longevity on the front line
The course will leverage both the perspective of the physician and patient, including biomarkers and deep diagnostics, things which clinics and academic institutions, which are bringing longevity medicine into their platforms, are already trying to apply.
Looking at developments in the past decade within the field, there’s a lot of promise around longevity technologies – it’s an area of exponential expansion. We are seeing more papers, the creation of more startups and biotechnology companies. It’s gaining momentum, and is very promising for Pharma, as it starts to look more seriously into the field.
Ricardo Gaminha Pacheco on the Pharma view
The course will cover a range of different opportunities for Phama, ranging from corporate venture funds, co-development, co-commercialization agreements and M&A activity as a whole. There are different ways of partnering within the industry; the more innovation is out there, the more promising this might be for Pharma, moving forward. We intend that the course will give more visibility to all of this.
Pharma is definitely playing attention to developments within the field; we are at a stage where things are very different now in 2023 versus what they were 10 years ago. Pharma really has been tracking a lot of the scientific breakthroughs out there, both at an academic level and from a private effort perspective as well. Looking at the whole field and the potential for new partnerships within the field, biotechs are also bringing those sources of external innovation internally within those companies to further develop their own pipeline – this is key for the industry and the Pharma companies out there. There are synergies to be explored.
Want to know more? Pre-register for Investing in Longevity 101 HERE: